泰格醫藥(03347.HK)斥100億人幣認購健康產業基金
泰格醫藥(03347.HK)公布,於昨日(12日),杭州泰格、杭州泰瓏、杭州產業及杭州高新投就成立基金訂立合夥協議。基金的註冊資本為200億元人民幣(下同),其中2億元將由杭州泰瓏認購,98億元將由杭州泰格認購,50億元將由杭州產業認購,50億元將由杭州高新投認購。
基金將重點投資涉及創新型醫療器械、生物醫藥、醫療服務、醫療信息化、數字療法、智能製造以及營養健康行業之企業。
杭州泰格是公司間接全資附屬,杭州泰瓏為杭州泰格持有99%權益的有限合夥人及由獨立第三方昭泰
有限合夥持有1%權益的普通合夥人持有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.